ArticleJournal of cellular and molecular medicine2026
Bioinformatics and Immunohistochemistry Reveal the Diagnostic and Mechanistic Role of the Cuproptosis-Related Genes SMOC2/THY1 in Liver Fibrosis.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cuproptosis, a newly identified form of programmed cell death, inhibits liver fibrosis in hepatic stellate cells. However, how cuproptosis influences liver fibrosis in other cells remains to be determined. We aimed to develop a diagnostic model for cuproptosis and to further investigate its role in liver fibrosis. We obtained datasets of patients with metabolic dysfunction-associated fatty liver disease from the Gene Expression Omnibus. A diagnostic model was established using WGCNA and machine learning, and the model demonstrated a satisfied accuracy in the training and validation sets. Single-cell RNA (scRNA) confirmed that cuproptosis is highly likely to occur in hepatocytes and likely promotes liver fibrosis through communication with macrophages and dendritic cells. Immunohistochemistry analyses revealed that THY1 localized to fibroblast membranes and SMOC2 localized to hepatocytes. Molecular docking and molecular dynamics were used to identify the most suitable therapeutic drugs and suggested that breviscapine may target THY1, which may have a therapeutic effect on liver fibrosis. These findings establish a diagnostic model based on cuproptosis-related genes for liver fibrosis, identify THY1 and SMOC2 as key diagnostic biomarkers, and propose a model in which the expression of these markers in hepatocyte are associated with fibrosis progression, potentially through immune-mediated mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.